Brief: Biomarin Pharmaceutical Q2 EPS USD 0.23
06/08/2026 21:04
BRIEF-Biomarin Pharmaceutical Q2 EPS USD 0.23 Aug 06 (Reuters) - Biomarin Pharmaceutical Q2 revenue USD 990 million vs. IBES estimate USD 926.9 million.
- Q2 adjusted EPS USD 1.2 vs. IBES estimate USD 0.69
- Q2 net income USD 45 million
Recent news on BioMarin Pharmaceutical
See all newsUS RESEARCH ROUNDUP-Analog Devices, IBM, Qualcomm
Brief: Biomarin Pharmaceutical Expects Q3 2026 Pre-Tax Charges Of $283 Million For Bought Ipr&D Expense
Brief: Biomarin Appoints Cara Bauer As Chief People Officer
Brief: Biomarin Pharmaceutical Enters Settlement And License Agreement With Ascendis Pharma On Sept 24, 2026
U.S. STOCKS ON THE MOVE-GitLab, California utilities, Herbalife